Chemomab Therapeutics Stock Price, News & Analysis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on developing therapeutics for fibro-inflammatory diseases with high unmet medical need. According to the company’s disclosures, its work is based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation. Chemomab’s lead product candidate is nebokitug (also referred to as CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential in clinical and preclinical studies.

Chemomab states that nebokitug has shown a favorable safety profile and has been generally well tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported positive results from multiple clinical trials of nebokitug, including the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), a rare, chronic and progressive liver disease characterized by inflammation, fibrosis and destruction of the bile ducts and associated with significant morbidity and potential early mortality. PSC currently has no cure and lacks effective treatment other than liver transplantation in advanced cases.

Nebokitug and the CCL24 Pathway

Based on Chemomab’s descriptions, nebokitug is a humanized IgG1 anti-CCL24 monoclonal antibody. CCL24 promotes cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor present on immune cells, fibroblasts and endothelial cells. Elevated CCL24 expression has been observed in liver biopsies from patients with PSC and in the periductal space, with CCL24 mainly expressed by inflammatory cells surrounding the bile ducts and cholangiocytes. Serum proteomic analyses in PSC have associated CCL24 levels with PSC-related pathways and disease severity. By neutralizing CCL24, nebokitug is intended to interrupt these fibro-inflammatory processes.

Chemomab reports that inhibition of CCL24 with nebokitug has demonstrated therapeutic benefits in multiple experimental PSC models. In patients, nebokitug has been associated with changes in biomarkers linked to fibrosis, inflammation and cholestasis. Across clinical and preclinical work, the company highlights nebokitug’s dual anti-inflammatory and anti-fibrotic activity as central to its potential to alter disease biology in fibro-inflammatory conditions.

Focus on Primary Sclerosing Cholangitis (PSC)

PSC is a key focus of Chemomab’s development strategy. The company has conducted the Phase 2 double-blind, placebo-controlled SPRING trial in patients with PSC, followed by an open-label extension (OLE). In the SPRING trial, patients received intravenous nebokitug or placebo, with primary endpoints focused on safety and tolerability and secondary endpoints including liver blood tests, enhanced liver fibrosis (ELF) score, the fibrogenesis biomarker PRO-C3 and liver stiffness measurements (LSM). These biomarkers have been shown in PSC studies to correlate with clinical outcomes such as transplant-free survival and disease progression.

Chemomab reports that nebokitug was generally safe and well tolerated compared to placebo at 15 weeks and that no safety signal was observed for up to 48 weeks of treatment in the OLE. The company states that nebokitug’s biological activity appeared dose dependent and was more evident in patients with moderate or advanced fibrosis, who represented about half of the SPRING study population and also comprise about half of all PSC patients. In these patients, nebokitug treatment was associated with numerical reductions in ELF score, PRO-C3 and LSM compared to placebo, with sustained improvements observed through 48 weeks at the 20 mg/kg dose.

According to Chemomab, reductions in ELF score and its fibrotic components (such as TIMP-1 and PIIINP), decreases in PRO-C3 and improvements in liver stiffness are all associated with better PSC outcomes. The company notes that in the SPRING trial, a greater proportion of nebokitug-treated patients with moderate/advanced fibrosis showed improvements across all three key biomarkers—ELF score, PRO-C3 and LSM—compared to placebo. These consistent changes within the same patients are presented as supporting evidence for nebokitug’s potential anti-fibrotic and anti-inflammatory effects in PSC.

Regulatory Designations and Development Path

Chemomab states that nebokitug has received Orphan Drug designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of PSC and systemic sclerosis, as well as FDA Fast Track status for the treatment of PSC in adults. The company has reported positive interactions with the FDA, including an End-of-Phase 2 meeting, and describes alignment on a Phase 3 registration strategy in PSC based on a single pivotal clinical trial using a composite of clinically relevant events as the primary endpoint. The company also reports regulatory alignment with the EMA on key aspects of the Phase 3 design.

Chemomab has indicated that it plans to advance the nebokitug PSC Phase 3 program, including through potential collaborations with strategic partners. It has also reported that the Chemistry, Manufacturing and Controls (CMC) strategy for nebokitug and the timing of certain nonclinical toxicology studies have been agreed with the FDA, allowing some toxicology work to proceed in parallel with the planned Phase 3 trial.

Broader Fibro-Inflammatory Disease Strategy

Beyond PSC, Chemomab describes nebokitug as having potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company notes that its nebokitug program for the treatment of systemic sclerosis has an open U.S. Investigational New Drug (IND) application and that preclinical and early clinical data support a role for CCL24 in the skin, lung and vascular manifestations of systemic sclerosis and other fibrotic conditions. Chemomab has highlighted studies showing that neutralizing CCL24 can modulate proteins involved in fibrosis, immune cell recruitment and inflammation.

In its communications, Chemomab emphasizes that it has reported positive results from several clinical trials of nebokitug in patients, and that data from the SPRING trial and related analyses have been presented at major scientific and medical meetings focused on liver disease and gastroenterology. The company also notes peer-reviewed publications describing nebokitug’s clinical data in PSC and review articles summarizing the role of CCL24 in fibro-inflammatory pathologies.

Capital Markets and Corporate Structure

Chemomab Therapeutics Ltd. is organized as a foreign private issuer and files reports with the U.S. Securities and Exchange Commission on Forms 20-F and 6-K. Its ordinary shares are represented by American Depositary Shares (ADSs) trading on the Nasdaq Capital Market under the symbol CMMB. The company has disclosed adjustments to the ratio of ADSs to ordinary shares, including a change to a ratio of one ADS representing eighty ordinary shares, which effectively functions as a reverse ADS split for ADS holders.

Through its SEC filings, Chemomab provides interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and details of capital-raising activities such as at-the-market (ATM) equity offering programs. The company has also reported that it may use ATM offerings to issue ADSs from time to time, subject to market conditions and internal decisions.

Research, Collaborations and Scientific Presence

Chemomab regularly highlights its participation in scientific conferences and investor events. The company has reported oral and poster presentations of nebokitug data at meetings including Digestive Disease Week, the British Society for Gastroenterology’s BSG Live, the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, and the European Association for the Study of the Liver (EASL) congress. It has also participated in rare disease–focused investor summits and global investment conferences, where it presents corporate overviews and clinical updates.

According to Chemomab, these activities help communicate nebokitug’s clinical data, its proposed mechanism of action via CCL24 blockade, and the design of the planned PSC Phase 3 trial to clinicians, researchers, patient advocates and the investment community. The company also reports expanding its intellectual property portfolio for nebokitug, including patents covering use in hepatic diseases and PSC in multiple territories such as the U.S., Europe, Japan, China and Russia.

Summary

In summary, Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company centered on targeting the CCL24 pathway in fibro-inflammatory diseases. Its lead candidate nebokitug is a monoclonal antibody designed to neutralize CCL24, with clinical data and regulatory designations supporting continued development in primary sclerosing cholangitis and potential applications in systemic sclerosis and other fibrotic conditions. The company’s disclosures emphasize biomarker-driven clinical evidence, regulatory dialogue with major agencies, and an expanding patent estate around nebokitug and CCL24-targeted therapies.